珍宝岛：11月24日召开董事会会议

Core Viewpoint - The company, Zhenbaodao, announced its board meeting to discuss the reappointment of the auditing firm for the fiscal year 2025, indicating ongoing governance and compliance efforts [1] Financial Performance - For the fiscal year 2024, Zhenbaodao's revenue composition is as follows: pharmaceutical manufacturing accounts for 87.78%, pharmaceutical distribution for 11.13%, and other businesses for 1.09% [1] - The current market capitalization of Zhenbaodao is 9.7 billion yuan [1] Regulatory Issues - Another company, identified as 688496, is under investigation by the China Securities Regulatory Commission (CSRC) due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases [1]